The roles and mechanisms of tumor infiltrating effector CD4+ TILs are complex and still being defined [44], and therefore the intriguing finding of effector CD4+ T cells providing therapeutic efficacy in the absence of CD8+ T cells will be the subject of future work. The gene discussed is CD8A; the disease is neoplasm.